SC 13G/A

 

 

ITEM 1. Securities and Exchange Commission

Washington, D.C. 20549

 

 

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1 )*

 

 

Phathom Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

71722W107

(CUSIP Number)

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 71722W107    Schedule 13G    Page 1 of 17

 

 1   

Names of Reporting Persons

 

The Carlyle Group Inc.

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

CO


CUSIP No. 71722W107    Schedule 13G    Page 2 of 17

 

 1   

Names of Reporting Persons

 

Carlyle Holdings I GP Inc.

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power 

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

CO


CUSIP No. 71722W107    Schedule 13G    Page 3 of 17

 

 1   

Names of Reporting Persons

 

Carlyle Holdings I GP Sub L.L.C.

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

OO (Limited Liability Company)


CUSIP No. 71722W107    Schedule 13G    Page 4 of 17

 

 1   

Names of Reporting Persons

 

Carlyle Holdings I L.P.

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

PN


CUSIP No. 71722W107    Schedule 13G    Page 5 of 17

 

 1   

Names of Reporting Persons

 

CG Subsidiary Holdings L.L.C.

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

OO (Limited Liability Company)


CUSIP No. 71722W107    Schedule 13G    Page 6 of 17

 

 1   

Names of Reporting Persons

 

TC Group, L.L.C.

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

OO (Limited Liability Company)


CUSIP No. 71722W107    Schedule 13G    Page 7 of 17

 

 1   

Names of Reporting Persons

 

Carlyle Investment Management L.L.C.

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

OO (Limited Liability Company)


CUSIP No. 71722W107    Schedule 13G    Page 8 of 17

 

 1   

Names of Reporting Persons

 

Carlyle Genesis UK LLC

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

Delaware

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

OO (Limited Liability Company)


CUSIP No. 71722W107    Schedule 13G    Page 9 of 17

 

 1   

Names of Reporting Persons

 

Abingworth LLP

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

England and Wales

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

3,496,808

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

3,496,808

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,496,808

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

6.1%

12   

Type of Reporting Person

 

PN


CUSIP No. 71722W107    Schedule 13G    Page 10 of 17

 

 1   

Names of Reporting Persons

 

Abingworth Bioventures 8 LP

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

England and Wales

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

2,061,702

    7   

Sole Dispositive Power

 

0

  

 8

  

Shared Dispositive Power

 

2,061,702

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,061,702

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

3.6%

12   

Type of Reporting Person

 

PN


CUSIP No. 71722W107    Schedule 13G    Page 11 of 17

 

 1   

Names of Reporting Persons

 

Abingworth Bioventures VII LP

 2   

Check the Appropriate Box if a Member of a Group

(a) ☐  (b) ☐

 

 3   

SEC Use Only

 

 4   

Citizenship or Place of Organization

 

England and Wales

Number of Shares Beneficially  Owned by Each Reporting Person

With

    5   

Sole Voting Power

 

0

    6   

Shared Voting Power

 

1,435,106

    7   

Sole Dispositive Power

 

0

    8   

Shared Dispositive Power

 

1,435,106

 9   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,435,106

10   

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11   

Percent of Class Represented by Amount in Row 9

 

2.5%

12   

Type of Reporting Person

 

PN


CUSIP No. 71722W107    Schedule 13G    Page 12 of 17

 

ITEM 2.    (a)    Name of Issuer:
     

Phathom Pharmaceuticals, Inc. (the “Issuer”).

   (b)    Address of Issuer’s Principal Executive Offices:
     

100 Campus Drive, Suite 102, Florham Park, NJ 07932

ITEM 3.    (a)    Name of Person Filing:
     

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

     

The Carlyle Group Inc.

     

Carlyle Holdings I GP Inc.

     

Carlyle Holdings I GP Sub L.L.C.

     

Carlyle Holdings I L.P.

     

CG Subsidiary Holdings L.L.C.

     

TC Group, L.L.C.

     

Carlyle Investment Management L.L.C.

     

Carlyle Genesis UK LLC

     

Abingworth LLP

     

Abingworth Bioventures 8 LP

     

Abingworth Bioventures VII LP

   (b)    Address or Principal Business Office:
     

The principal business address of each of Abingworth LLP, Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.

   (c)    Citizenship of each Reporting Person is:
     

Each of Abingworth LLP, Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.

   (d)    Title of Class of Securities:
     

Common Stock, par value $0.0001 per share (“Common Stock”).

   (e)    CUSIP Number:
     

71722W107


CUSIP No. 71722W107    Schedule 13G    Page 13 of 17

 

ITEM 4.

Not applicable.

 

ITEM 5.

Ownership.

(a-c)

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of November 7, 2023, based upon 57,252,519 shares of Common Stock outstanding, as disclosed in the Issuer’s Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 9, 2023.

 

Reporting Person

   Amount
beneficially
owned
     Percent
of class
    Sole
power to
vote or to
direct the
vote
     Shared
power to
vote or to
direct the
vote
     Sole power
to dispose
or to direct
the
disposition
     Shared
power to
dispose or to
direct the
disposition
 

The Carlyle Group Inc.

     3,496,808        6.1     0        3,496,808        0        3,496,808  

Carlyle Holdings I GP Inc.

     3,496,808        6.1     0        3,496,808        0        3,496,808  

Carlyle Holdings I GP Sub L.L.C.

     3,496,808        6.1     0        3,496,808        0        3,496,808  

Carlyle Holdings I L.P.

     3,496,808        6.1     0        3,496,808        0        3,496,808  

CG Subsidiary Holdings L.L.C.

     3,496,808        6.1     0        3,496,808        0        3,496,808  

TC Group, L.L.C.

     3,496,808        6.1     0        3,496,808        0        3,496,808  

Carlyle Investment Management L.L.C.

     3,496,808        6.1     0        3,496,808        0        3,496,808  

Carlyle Genesis UK LLC

     3,496,808        6.1     0        3,496,808        0        3,496,808  

Abingworth LLP

     3,496,808        6.1     0        3,496,808        0        3,496,808  

Abingworth Bioventures 8 LP

     2,061,702        3.6     0        2,061,702        0        2,061,702  

Abingworth Bioventures VII LP

     1,435,106        2.5     0        1,435,106        0        1,435,106  

Abingworth Bioventures 8 LP is the record holder of 2,061,702 shares of Common Stock and Abingworth Bioventures VII LP is the record holder of 1,435,106 shares of Common Stock.

The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of


CUSIP No. 71722W107    Schedule 13G    Page 14 of 17

 

Abingworth LLP. Each of Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by them. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures 8 LP and Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.

 

ITEM 6.

Ownership of Five Percent or Less of a Class.

Not applicable.

 

ITEM 7.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

 

ITEM 8.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

 

ITEM 9.

Identification and Classification of Members of the Group.

Not applicable.

 

ITEM 10.

Notice of Dissolution of Group.

Not applicable.

 

ITEM 11.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


CUSIP No. 71722W107    Schedule 13G    Page 15 of 17

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2024

 

The Carlyle Group Inc.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Chief Financial Officer
Carlyle Holdings I GP Inc.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Managing Director and Chief Financial Officer
Carlyle Holdings I GP Sub L.L.C.
By: Carlyle Holdings I GP Inc., its sole member
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Managing Director and Chief Financial Officer
Carlyle Holdings I L.P.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Managing Director
CG Subsidiary Holdings L.L.C.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Managing Director
TC Group, L.L.C.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Managing Director


CUSIP No. 71722W107    Schedule 13G    Page 16 of 17

 

Carlyle Investment Management L.L.C.
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Chief Financial Officer
Carlyle Genesis UK LLC
By: Carlyle Investment Management L.L.C., its sole member
By:   /s/ Anne Frederick, attorney-in-fact
Name:   John C. Redett
Title:   Chief Financial Officer
Abingworth LLP
By:   /s/ John Heard
Name:   John Heard
Title:   Authorized Signatory
Abingworth Bioventures 8 LP
By:   /s/ John Heard
Name:   John Heard
Title:   Authorized Signatory
Abingworth Bioventures VII LP
By:   /s/ John Heard
Name:   John Heard
Title:   Authorized Signatory


CUSIP No. 71722W107    Schedule 13G    Page 17 of 17

 

LIST OF EXHIBITS

 

Exhibit No.

  

Description

24    Power of Attorney.
99    Joint Filing Agreement (previously filed).
EX-24

Exhibit 24

POWER OF ATTORNEY

The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederick, Erica Herberg, Anat Holtzman, Andrew Howlett-Bolton, Joshua Lefkowitz, David Lobe, Elizabeth Muscarella, Sanket Patel, Robert Rosen, and Catherine Ziobro, or any of them signing singly, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

 

  (1)

prepare, execute in the name of each Carlyle Company and on behalf of each Carlyle Company, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of Forms D (“Form D”) required to be filed in accordance with Rule 503 (“Rule 503”) promulgated with respect to Sections 4(2), 4(6) and 3(b) of the Securities Act of 1933, as amended (the “1933 Act”) and reports required by Sections 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended (the “1934 Act”) or any rule or regulation of the SEC;

 

  (2)

prepare and execute for and on behalf of each Carlyle Company, in the undersigned’s capacity as a Chairman, authorized person, officer and/or director of each Carlyle Company, federal and state securities laws filings including without limitation Forms D pursuant to Rule 503 and Schedules 13D and 13G and Forms 3, 4, and 5 in accordance with Sections 13(d) and 16(a) of the 1934 Act and the rules thereunder;

 

  (3)

do and perform any and all acts for and on behalf of each Carlyle Company that may be necessary or desirable to complete and execute any such federal and state securities laws filings including without limitation Forms D, Schedules 13D and 13G and Forms 3, 4, and 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and the securities administrators of any state, the District of Columbia, the Commonwealth of Puerto Rico, Guam and the United States Virgin Islands or their designees and any stock exchange or similar authority; and

 

  (4)

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.


The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted, whether the same needs to be executed, taken or done by him in his capacity as a current or former member, partner, shareholder, director or officer of any company, partnership, corporation, organization, firm, branch or other entity connected with, related to or affiliated with any of the entities constituting the Carlyle Companies or entities that directly or indirectly hold interests in the Carlyle Companies.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned’s responsibilities to comply with federal and state securities laws, including without limitation Rule 503 of the 1933 Act or Section 13 and Section 16 of the 1934 Act.

This Power of Attorney and all authority conferred hereby shall not be terminated by operation of law, whether by the death or incapacity of the undersigned or by occurrence of any other event. Actions taken by an attorney-in-fact pursuant to this Power of Attorney shall be as valid as if any event described in the preceding sentence had not occurred, whether or not the attorney-in-fact shall have received notice of such event. Notwithstanding the foregoing, (i) in the event that an attorney-in-fact is no longer employed by The Carlyle Group Employee Co., L.L.C. or its affiliates, this Power of Attorney and all authority conferred hereby shall be immediately terminated with respect to such Attorney, and (ii) the undersigned may terminate or revoke this Power of Attorney at any time.

For purposes hereof, the “Carlyle Companies” shall consist of: (i) Carlyle Group Management L.L.C., The Carlyle Group Inc., Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., TC Group, L.L.C., Carlyle Holdings II GP L.L.C., Carlyle Holdings II L.L.C., CG Subsidiary Holdings L.L.C., TC Group Investment Holdings Limited Partner L.L.C., TC Group Investment Holdings, L.P., Carlyle Holdings III GP L.P., Carlyle Holdings III GP Sub L.L.C., Carlyle Holdings III L.P., TC Group Cayman L.P., TC Group Sub L.P., TC Group Investment Holdings Sub L.P., TC Group Cayman Investment Holdings, L.P., TC Group Cayman Investment Holdings Sub L.P., TC Group Cayman, L.P., TC Group Cayman Sub L.P., Five Overseas CG Investment L.L.C. and (ii) the subsidiaries and affiliates of the foregoing in clause (i), including without limitation investment funds sponsored directly or indirectly by one or more of the Carlyle Companies.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of October, 2023.

 

By:   /s/ John C. Redett
Name:   John C. Redett
Title:   Chief Financial Officer